A modified dexamethasone suppression test for endogenous depression.

Area of Science:

• Endocrinology
• Neuroscience
• Psychiatry

Background:

• The standard dexamethasone suppression test (DST) is used to assess the central nervous system-pituitary-adrenal axis.
• Simplifying the DST could improve its clinical utility.

Purpose of the Study:

• To simplify the dexamethasone suppression test (DST) by reducing the dexamethasone (DEX) dosage and shortening the sampling time.
• To evaluate the sensitivity and specificity of a modified 0.5 mg DST compared to the standard 1.0 mg DST.

Main Methods:

• Normal volunteers received incremental DEX doses (0.125-1.0 mg) with single morning cortisol sampling.
• Endogenously depressed patients and controls underwent both standard 1.0 mg DST and simplified 0.5 mg DST.
• Cortisol levels were measured post-DEX to identify nonsuppressors.

Main Results:

• The 0.5 mg DEX dose was the minimum to suppress cortisol in all normal subjects.
• The simplified 0.5 mg DST identified more nonsuppressors in endogenously depressed patients (45%) compared to the standard 1.0 mg DST (20%).
• Specificity of the 0.5 mg DST was comparable to the standard test.

Conclusions:

• The single-sample 0.5 mg DST is a more sensitive diagnostic tool than the standard 1.0 mg DST.
• This simplified DST offers a potentially more effective method for evaluating the HPA axis in depression.
• The modified test maintains comparable specificity to the conventional DST.